Innovodigm, a healthtech startup focused on next-gen vaccine delivery, has raised ₹5.5 crore in a seed funding round led by the Indian Angel Network (IAN), which contributed ₹4.5 crore. The remaining investment came from PadUp Ventures.
The company stated that the funds will be used to enhance operational efficiency, expand infrastructure, and grow its team, as it moves toward third-party preclinical validation and prepares for clinical trials.
Founded in 2020 by Jhimli Manna and Ayan Chatterjee, Innovodigm is pioneering a Microneedle Array Patch (MAP) platform — a needle-free, thermostable vaccine delivery system aimed at overcoming the challenges of conventional injectable immunization. Unlike traditional vaccines that require stringent cold-chain storage, Innovodigm’s MAP technology offers thermostabilized formulations that can remain viable for up to 120 days at 40°C.
This breakthrough could help minimize cold-storage costs, reduce medical waste, and expand vaccine accessibility in remote or underserved regions.
The startup has already attracted institutional recognition. Its MAP platform was named among the Top 2 Technologies at the Nano Electronics Showcase 2025, hosted by the Ministry of Electronics and IT. Innovodigm has also signed a Material Transfer Agreement (MTA) with an Indian vaccine manufacturer, paving the way for third-party validation ahead of expected clinical trials in 2026.
A spinout from IIT Kharagpur’s Microelectronics and MEMS Lab, Innovodigm sits at the crossroads of biomedical innovation and public health. It aims to offer a low-cost, scalable immunization platform suited for both domestic and global markets.
The company plans to expand the application of its MAP platform to a broad range of vaccines, including measles, hepatitis, influenza, and COVID-19 boosters. Looking ahead, Innovodigm also envisions building decentralized manufacturing hubs to localize production and streamline distribution, particularly across low- and middle-income countries.
